MedTrace Logo

A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)

NCT06213259 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2026-04-01

No results posted yet for this study

Summary

This phase 1 study will consist of two parts: Phase 1a is a single-dose study, and will evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary pharmacodynamics (PD) in healthy participants. Phase 1b is a multiple doses study, and will evaluate the safety, tolerability, PK and preliminary PD in participants with rheumatoid arthritis (RA).

Conditions

Interventions

DRUG

KD6005

Biological: KD6005, SQ

DRUG

Placebo

Placebo, SQ

Sponsors & Collaborators

  • Shanghai Kanda Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yi Fang · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-06
Primary Completion
2025-01-10
Completion
2025-01-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06213259 on ClinicalTrials.gov